2 consecutive days of limit-up. On the 24th, the regenerative medicine product, "Acugo intracerebral transplantation injection", was conditionally approved for manufacturing and sales by the Ministry of Health, Labor and Welfare, but additional data submission was requested and shipment approval was postponed. The company submitted additional data since March, and after evaluation, the approval was granted. The company explained that after about 2 more rounds of production, standard testing, and similar characteristic analysis to the additional data submitted since March, shipment will be possible after obtaining partial approval for changes in approval matters, and investor concerns seem to have subsided.
サンバイオ---2営業日連続ストップ高、投資家の懸念が後退
SanBio---two consecutive business days of limit-up, easing investor concerns.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.